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ABSTRACT 
Atherosclerosis (ATH) is recognized as a chronic inflammatory condition and it is the leading 
cause of cardiovascular disease. Atherogenesis is characterized by the infiltration of low density 
lipoprotein (LDL) through the endothelial layer, and migration of activated peripheral blood 
lymphocytes (PBL) and monocytes (PBMN) that contribute to a pro-inflammatory state in specific 
locations. However, the functional interaction between immunity and LDL metabolism is still not 
fully understood. One hypothesis for the etiopathogeny of ATH may be associated with an ongoing 
inflammatory process caused by a pro-oxidant/anti-oxidant imbalance induced by metals such as 
iron (Fe) or copper (Cu).  Interestingly, ceruloplasmin (Cp) is a multicopper oxidase with a relevant 
role in Fe metabolism and oxidation of LDL, but also an acute-phase protein involved in the 
inflammatory process.  
Herein, we intended to study by flow cytometry the effect of putative pro-atherogenic immune 
stimuli on the expression of Cp at the surface of human peripheral blood mononuclear cells 
(PBMC), and search for a putative association with LDL oxidation.  Additionally, a population of 
Familial Hypercholesterolemia (FH) patients was used as a clinical model of ATH to clarify the 
physiologic interplay between inflammation, Fe/Cu and lipid metabolism at systemic level in this 
disease. 
The obtained results showed that higher cell surface expression of Cp was consistently observed 
in PBMN compared to PBL, in activated vs non-activated cells and in non-T cells vs T cells. Also, 
PBMC surface expression of Cp was differently modulated by several tested treatments. In 
particular, various modulators caused opposite effects on Cp expression of PBMN compared to 
PBL, suggesting a specific cell-type regulation for this protein. Specifically, it was observed that 
different sources of Fe might activate specific regulation mechanisms of Cp. Until now, due to 
technical limitations it was not possible to demonstrate an association between PBMC surface Cp 
expression and oxidation of LDL, but this issue should be addressed in future experiments. Of 
notice, IL-1β which was found to significantly increase PBMN surface Cp expression in vitro, was 
increased in serum from FH patients and positively correlated with total cholesterol and ApoB. 
However, the fact that no correlation was found between IL-1β and serum Cp (sCp)/oxidated LDL 
suggest that at systemic level, IL-1β may not be a contributing factor for oxidation of LDL by sCp. 
However, the role of PBMC surface Cp expression on LDL oxidation, namely in specific 
inflammatory states, remains to be established. 
In summary, the results of this study demonstrate that specific pro-atherogenic conditions are 
involved in the modulation of Cp expression at surface of PBMC and thus, suggest a possible a role 
of Cp in ATH.  
 
Key Words: Atherosclerosis - Ceruloplasmin - Mononuclear cells - Iron Metabolism  
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SUMÁRIO 
A aterosclerose (AT) é a principal causa de doenças cardiovasculares (DCV). Muito embora 
esta doença tenha sido numa primeira fase considerada como uma simples deposição de lípidos, 
avanços substanciais nas áreas da ciência experimental permitiram revelar o importante papel da 
inflamação nesta patologia. Actualmente, a AT já não é reconhecida como uma simples 
consequência de envelhecimento considerando os factores de risco tradicionalmente aceites no seu 
envolvimento, mas antes como uma doença inflamatória crónica que pode ser convertida num 
evento clínico agudo por ruptura de placas ateroscleróticas e consequente trombose. 
A formação da placa aterosclerótica (aterogénese) caracteriza-se por uma infiltração e activação 
precoce de monócitos e linfócitos (células mononucleares) que contribuem para um estado pró-
inflamatório localizado em regiões de endotélio disfuncional. Adicionalmente, a passagem de 
lipoproteínas de baixa densidade (LDL) através da camada endotelial e a sua oxidação constituem 
eventos precoces da aterogénese. Contudo, os mecanismos fisiológicos envolvidos na interacção 
funcional entre as células imunitárias e a oxidação das LDL não estão completamente esclarecidos. 
Uma hipótese para a etiopatogenia da AT poderá estar associada à existência de um processo 
inflamatório contínuo relacionado com stress oxidativo induzido por metais, tais como ferro (Fe) 
ou Cobre (Cu). A ceruloplasmina (Cp) é uma proteína de fase aguda da família das multicobre 
oxidases com funções importantes no metabolismo do Fe, principalmente devido à sua actividade 
ferroxidásica. Para além disso, esta proteína apresenta potencial pró- e anti-oxidante, actividades 
relevantes no contexto do stress oxidativo característico deste processo. 
O objectivo geral deste estudo foi investigar e caracterizar in vitro alguns dos mecanismos 
subjacentes à relação funcional entre inflamação, metabolismo do Fe/Cu e a homeostase lipídica, 
de forma a adquirir novos conhecimentos sobre a fisiopatologia da AT. Em particular, estudaram- 
os efeitos de status de Fe e Cu alterado, citocinas pró-inflamatórias e outros imunomoduladores na 
expressão de Cp à superfície de células mononucleares de sangue periférico (PBMC). Este estudo 
foi realizado através da utilização de citometria de fluxo, que possibilitou caracterizar a expressão 
da Cp membranar em subpopulações leucocitárias específicas de monócitos (PBMN) e linfócitos 
(PBL) de sangue periférico. Posteriormente, avaliou-se a possível associação entre a modulação da 
expressão de Cp membranar nas condições testadas e a oxidação de LDL. Adicionalmente, 
realizou-se a caracterização laboratorial de uma população de doentes diagnosticados com 
Hipercolesterolemia Familiar (HF), como um modelo clínico de AT. Neste contexto, pretendeu-se 
complementar os estudos in vitro procurando a existência de associações entre os parâmetros do 
metabolismo do Fe/Cu, lípidos e inflamação medidos a nível sistémico.  
Os resultados obtidos através de citometria de fluxo mostraram consistentemente que a 
expressão de Cp à superfície de PBMN é maior comparativamente com PBL e que em ambas as 
populações as células activadas apresentam maiores níveis de expressão desta proteína que as suas 
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homólogas não activadas. Além disso, mostrou-se que dentro das subpopulações de PBL, são as 
células não-T que possuem maior expressão de Cp à sua superfície em comparação com as células 
T. Por outro lado, os resultados obtidos através das experiências de modulação mostraram que a Cp 
membranar das duas populações celulares em estudo é diferentemente regulada na presença dos 
diversos estímulos. Em condições de status de Fe alterado foi observado que a Cp à superfície de 
PBMC é diferentemente regulada nos dois tipos celulares testados, e parecem existir mecanismos 
de regulação específicos consoante o dador de Fe utilizado. Adicionalmente, a alteração do status 
de Cu não produziu modificações significativas na expressão de Cp à superfície de PBMC. Estas 
observações não corroboraram resultados obtidos anteriormente por outros autores e devem-se 
provavelmente ao curto espaço de tempo de incubação que não possibilitou visualizar o efeito de 
variação da concentração deste metal na estabilidade da Cp.  
Em relação aos tratamentos com as citocinas e outros imunomodulatores observou-se de uma 
forma geral que a interleucina (IL)-1β, lipopolissacarídeo, e forbol 12-miristato 13-acetato 
induziram o aumento da expressão de Cp à superfície dos PBMN enquanto que a diminuíram nos 
PBL, sugerindo que a Cp membranar destas populações celulares poderá ser regulada 
especificamente devido às funções particulares e  diferenças de cada tipo celular durante a resposta 
inflamatória. Os tratamentos com interferão-γ e IL-2 diminuíram a expressão de Cp à superfície de 
PBMN e PBL em incubações de longa duração, enquanto os tratamentos efectuados com os 
mediadores IL-6, IL-8, factor estimulador de colónia de macrófagos e o factor de necrose tumoral-
α não resultaram variações na expressão membranar de Cp em ambos os tipos celulares. 
Provavelmente, a expressão de Cp à superfície de PBMC poderá ser nestes casos modulada em 
curtos espaços de tempo, pelo que as condições experimentais utilizadas não permitiram confirmar 
esta hipótese. A influência de espécies reactivas de azoto na expressão de Cp à superfície de PBMC 
foi igualmente testada realizando o tratamento com S-nitroso-N-acetilpenicilamina(dador de óxido 
nítrico), verificando-se que na presença deste tipo de condições de stress oxidativo são 
especificamente os PBMN que aumentam a expressão de Cp à sua superfície. Estes resultados 
sugerem que em estado pró-inflamatórios e de stress oxidativo a Cp expressa à superfície dos 
PBMN parece estar mais associado ao papel de proteína de fase aguda descrito para a forma 
circulante da Cp enquanto nos PBL esta proteína parece estar mais associada à regulação de status 
de Fe intracelular de modo a permitir a proliferação deste tipo de células após estimulação. 
Posteriormente, avaliou-se uma possível associação entre a indução de Cp à superfície de PBMC e 
oxidação das LDL no meio. Contudo, limitações técnicas impediram a confirmação desta hipótese 
neste trabalho. No entanto, a detecção de níveis de LDL oxidada (oxLDL) no sobrenadante de 
culturas em que Cp membranar de PBMN fora induzida por IL-1β, sugere a existência de potencial 
pró-oxidante na forma membranar de Cp. Esta observação carece contudo de confirmação após 
optimização de procedimento experimental utilizado. 
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Os resultados decorrentes da caracterização clínica do grupo de indivíduos diagnosticados com 
HF revelaram que estes doentes apresentam diferenças nos parâmetros relacionados com o 
metabolismo dos lípidos, consistentes com o seu diagnóstico molecular que mostra a existência de 
mutações genéticas em componentes do metabolismo lipídico. Nestes doentes foram ainda 
encontrados valores mais elevados de ferritina, oxLDL e IL-1β comparativamente com os 
indivíduos saudáveis. Além disso, nos doentes HF observou-se a existência de correlações positivas 
entre Cp circulante (sCp) e oxLDL, concordante com potencial pró-oxidante desta proteína, e entre 
sCp e proteína C reactiva - duas proteínas de fase aguda presentes em processos inflamatórios 
envolvidos na progressão desta doença. Foi também encontrada a correlação positiva de IL-1β com 
níveis de colesterol total e ApoB, parâmetros associados com risco aumentado de DCV. Contudo, o 
facto de não ter sido observada nenhuma correlação entre os níveis de IL-1β e sCp / oxLDL nestes 
indivíduos sugere que a nível sistémico a IL-1β parece não contribuir para o aumento de acção pró-
oxidante da sCp. No entanto não é de excluir a possibilidade de um possível papel fisiológico de 
Cp expressa à superfície das PBMC a nível local nas placas ateroscleróticas. 
Em conclusão, os resultados deste estudo demonstram que modulatores específicos de Fe/Cu e 
mediadores inflamatórios putativamente associados a estados pró-aterogénicos podem estar, pelo 
menos em parte, envolvidos na modulação da forma membranar da Cp em PBMC, sugerindo um 
possível papel da Cp à superfície dessas células durante a aterogénese.  
 
 
Palavras Chave: Aterosclerose - Ceruloplasmina - Células Mononucleares - Metabolismo do 
Ferro 
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INTRODUCTION 
1. Atherosclerosis and Cardiovascular Disease 
Cardiovascular disease (CVD) is the main cause of death in Western societies, being 
responsible for approximately 50% of all deaths [1]. Also, the economic and social difficulties 
caused by CVD are immense, constituting the greatest single cause of adult disability and a 
serious economic burden [2]. 
CVD is a collective term that comprises the clinical manifestations of coronary heart disease 
(CHD) and cerebrovascular disease, both of which have as a primary cause Atherosclerosis 
(ATH). [3] 
The development of CVD involves genetic factors as well other acquired and modifiable risk 
factors. Smoking, hypercholesterolemia, diabetes mellitus and hypertension, among others are 
some of the main players in the development of this disease; however the major underlying 
cause leading to CVD is indeed ATH. [2, 4] 
ATH is considered to be a complex multifactorial disease [5] that begins in the first decade 
of life, generally affecting the large arteries [2] as fatty streak lesions start to form in the artery 
wall. These early lesions are characterized by inflammation, lipid accumulation, cell death and 
fibrosis. Over time, they will mature and develop new characteristics as continued recruitment 
of mononuclear cells (Figure 1A), proliferation and migration of smooth muscle cells (SMC) 
occurs [2, 6]. This type of lesions, are then called atheromas or atherosclerotic plaques (Figure 
1B) [7].  
Clinical complications of ATH can arise from plaques causing flow-limiting stenoses, as 
significant narrowing of the arterial lumen occurs [8]. The most severe clinical events happen 
however after the rupture of a plaque (Figure 1C). This usually ensues when the combined 
efforts of the physical forces of blood ﬂow and intensiﬁed inﬂammatory activation (that may 
lead to local proteolysis) disrupt the arterial wall [3, 6, 7]. These actions will eventually expose 
prothrombotic material from the interior of the plaque to the blood, triggering a thrombus that 
can cause sudden thrombotic occlusion of the artery at the site of disruption and the subsequent 
blockage of blood flow. In the heart, this leads to myocardial infarction (MI) and heart failure, 
whereas in the arteries that perfuse the brain, it can cause ischemic stroke and transient ischemic 
attacks [6].  
Fig. 1 - Role of inﬂammation in all stages of atherosclerosis. A) Leukocyte recruitment to the nascent atherosclerotic lesion. B) T 
lymphocytes join macrophages in the intima during lesion evolution. C) Alterations in extracellular matrix thin the ﬁbrous cap, renders 
it weak and susceptible to rupture, triggering the thrombus that causes most acute complications of ATH. (From Libby et al. [9]) 
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Table I - Risk factors for Development of ATH 
(From Greaves et al. [2]) 
1.1 Inflammation and Atherosclerosis 
During the last decades, experimental, clinical, and epidemiological studies have shed light 
on several key aspects related to this disease. Although ATH was formerly considered a bland 
lipid storage disease, the substantial advances in basic and experimental science have 
illuminated the pivotal role of inflammation in this disease [9], particularly the role of 
monocytes/macrophages and lymphocytes, and the defined series of changes that occur in the 
vessel during atherogenesis. It is now clear that ATH is not simply an inevitable degenerative 
consequence of ageing, but rather a chronic inflammatory condition that can be converted into 
an acute clinical event by plaque rupture and thrombosis [1]. 
Multiple independent pathways of evidence 
now identify inflammation as a key regulatory 
process that links multiple risk factors for ATH 
and its complications with altered arterial biology 
[10]. In this context, epidemiologic studies have 
identified many genetic and environmental risk 
factors (Table I) that seem to cause an impact on 
the inflammatory and immunological response of 
the organism [11]. Thus, cardiovascular risk 
factors are essentially injuries or insults to which 
the body adapts by continuously triggering a 
response throughout years of exposure [12].  
This kind of compensatory response occurs preferentially at sites of hemodynamic strain 
[13], segments with low average shear but high oscillatory shear stress [14]. The normal 
homeostatic properties of the endothelium are then altered, and it becomes dysfunctional. Thus, 
the different forms of injury increase the adhesiveness of the endothelium with respect to 
leukocytes or platelets, as well as its permeability. They also induce the endothelium to have 
pro-coagulant instead of anticoagulant properties and to form vasoactive molecules, cytokines, 
and growth factors. If the offending agent or agents are not successfully dealt with by the 
immune system, and the inflammation as a chance to progress and continue indefinitely, the 
inflammatory response converts from a protective to an injurious response [15].  
Such constant or repetitive injury can also stimulate the affected tissue to repair or wall off 
the damage by means of a fibroproliferative response, which, when excessive, diminishes the 
functional capacity of the tissue or organ and becomes part of the disease process. Because of 
this process, initially, the only cells thought to proliferate during expansion of atherosclerotic 
lesions were SMC [15]. However, as it is, most of the cells found in atheromas are blood-borne 
immune cells, and the remainder are then vascular endothelial and SMC [7]. Therefore, 
replication of monocyte-derived macrophages and T cells is probably equal importance during 
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the expansion of atheromas [16]. The ability of macrophages to produce cytokines (such as 
tumor necrosis factor α (TNF-α), interleukin (IL)-1 and transforming growth factor β), 
proteolytic enzymes (particularly metalloproteinases), and growth factors (such as platelet-
derived growth factor and insulin-like growth factor I) may be critical in the role of these cells 
during the damage and repair that ensues as the lesions progress [15]. 
Many of the immune cells in the atheroma exhibit signs of activation and produce pro-
inﬂammatory cytokines [7]. Activated macrophages express class II histocompatibility antigens 
that allow them to present antigens to T lymphocytes [17]. Thus, it is not surprising that cell-
mediated immune responses may be involved in atherogenesis, since both CD4 and CD8 T cells 
are present in the lesions at all stages of the process [18]. This smoldering inﬂammatory state 
may lead to detectable blood levels of pro-inﬂammatory cytokines and other acute phase 
reactants. C-reactive protein (CRP) and IL-6 are elevated in patients with unstable angina and 
MI; high levels of these factors also predict a poor outcome [19, 20]. Furthermore, other 
inﬂammatory markers appear elevated in these patients, including IL-7, IL-8, soluble CD40 
ligand, and the CRP-related protein pentraxin-3 [21-23]. 
 The fact that several different inﬂammatory markers with different biological activities 
contribute to significantly increase the risk for CVD makes it unlikely that any of these 
particular markers actually causes the disease. Instead, the elevated levels may reﬂect an 
exacerbated inﬂammatory state in the atheroma, which promotes or causes plaque rupture, 
thrombosis, and ischemia [7]. In regard to possible causes of endothelial dysfunction, high 
levels of serum cholesterol are probably unique in being sufficient to drive the development of 
ATH in humans and experimental animals, even in the absence of other recognizable risk 
factors [11]. 
Free radical formation caused by cigarette smoking, hypertension, and diabetes mellitus 
causes focal endothelial activation in large- and medium-sized arteries [24]. Of these risk 
factors, smoking was shown to be one of the main factors in enhancing the risk of development 
of ATH, as it increases the lifetime risk in two-fold [25]. Likewise, the lack of exercise and the 
associated adiposity, in addition to a high intake of saturated fats and a low intake of certain 
vitamins, are commonly associated with an increased CHD risk in the general population [26]. 
Also, genetic alterations, as elevated plasma homocysteine concentrations that increases 
collagen production [27] and decreases the availability of nitric oxide [28], infectious 
microorganisms such as herpes viruses or Chlamydia pneumoniae and/or combinations of these, 
and other factors [29, 30], can contribute to atherogenesis [15]. 
The mechanism of action of these factors is, at least in part, thought to be associated with 
altered plasma levels of lipids and atherogenic lipoproteins. In fact, high levels of low-density 
lipoprotein (LDL) cholesterol and low levels of high-density lipoprotein (HDL) cholesterol have 
consistently been shown to be connected with CHD risk. [26]  
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1.2 Atherogenesis 
The early phase of atherosclerotic disease is best explained as an inﬂammatory response 
elicited by retention of lipoproteins in the arterial intima [7] 
at sites of dysfunctional endothelium, where disturbed flow 
dynamics cause modifications at the cellular and molecular 
level [14]. This occurs when plasma levels of the 
cholesterol-rich very low-density lipoprotein and LDL rise, 
and the lipoproteins inﬁltrate the artery wall to an extent that 
exceeds the capacity for elimination, and so they are retained 
in the extracellular matrix (Figure 2) [24].  
The oxidation of LDL is believed to occur locally within the arterial wall after retention [31]. 
Once LDL enters the vascular wall, the lipoproteins lose the protection from plasma anti-
oxidants [32], thus their modification is promoted by oxidation, glycation (in diabetes), 
aggregation, association with proteoglycans, or incorporation into immune complexes [33, 34]. 
Presumably reactive oxygen species (ROS) produced by endothelial cells (EC), macrophages, 
proteins and several enzymes which occur in human atherosclerotic lesions have an important 
role at this stage [32].  
EC and vascular SMC have been shown to oxidize LDL in culture [35-38], as have a number 
of enzymes [39-43] and proteins, such as ceruloplasmin (Cp) [44]. In some experimental 
situations, it was observed that administration of anti-oxidants can delay the progression of 
atherosclerotic lesions that develop in the face of hyperlipidemia, however human clinical trials 
have repeatedly failed to corroborate the concept that anti-oxidant vitamin therapy can improve 
clinical outcomes [9].  
The oxidative stress generated within the intima [11] is a major cause of injury to the 
endothelium and underlying smooth muscle [45] and eventually evokes an inflammatory 
response in the arterial wall [11]. This response triggers the endothelial expression of adhesion 
molecules which cause blood cells rolling on the vascular surface to adhere at the site of 
activation [46] (such as vascular cell adhesion molecule-1 (VCAM-1) [47] and P-selectin [48]) 
and chemoattractant factors (such as monocyte chemoattractant protein 1 (MCP-1) and IL-8) 
that direct the migration and diapedesis of circulating monocytes and other leukocytes into the 
vascular intima of the arterial wall [49, 50] to neutralize or remove the offending agents [15]. 
Ultimately, this culminates in the formation of a ﬁbrous plaque in that site [51], as illustrated in 
Fig. 1A and 1B. If the immune response is not successful, it can continue indefinitely. In doing 
so, the inflammatory response stimulates migration and proliferation of SMC that become 
intermixed with the area of inflammation to form an intermediate lesion [15].  
The degree to which LDL is modified can vary greatly [45, 52] but once modified it can be 
internalized by macrophages by means of the scavenger receptors on the surfaces of these cells 
Fig. 2 - Infiltration of LDL into the 
endothelium. When it is retained in the 
intima, it can undergo oxidative 
modification (From Hanson et al. [7]) 
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[33, 34, 45, 53]. The internalization leads to the formation of lipid peroxides and facilitates the 
accumulation of cholesterol esters, resulting in their cellular activation and modification into 
foam cells [15]. Because these scavenger receptors are not down-regulated by increases of 
intracellular cholesterol levels, as it happens with the native LDL receptor, foam cells 
continually engulf modiﬁed LDL [54] until their eventual death, contributing to the 
amplification of the inflammatory process and the formation of the necrotic core found in 
advanced lesions [11]. 
Removal and sequestration of modified LDL are important parts of the initial, protective role 
of macrophages in the inflammatory response [52, 53] and minimize the effects of modified 
LDL on EC and SMC [15]. In fact, oxidized LDL (oxLDL) has numerous atherogenic 
properties on its own [55] and the bioactive phospholipids released by its modification can 
activate EC [56]. Furthermore, in addition to its ability to injure these cells [45], modified LDL 
is chemotactic on itself for other monocytes and can up-regulate the expression of genes for 
macrophage colony-stimulating factor (M-CSF) [57] and MCP-1 [58] derived from EC [15].  
Thus, a vicious circle of inflammation, modification of lipoproteins, and further 
inflammation can be maintained in the artery by the presence of these lipids [15]. Specifically, 
mediators of inflammation such as TNF-α, IL-1 and M-CSF increase binding of LDL to 
endothelium and smooth muscle, and increase the transcription of the LDL-receptor gene [59].  
 
1.3 Atherosclerotic Plaque Microenvironment 
Within the inflamed arterial intima an altered cellular microenvironment is established, 
allowing the progression of ATH lesions [60, 61]. Interactions between macrophages foam 
cells, T helper (Th) 1 and Th2 cells eventually establishes the chronic inflammatory process 
[11]. 
A variety of different chemokines and cytokines mediates chemotactic recruitment of 
adherent monocytes and lymphocytes to the forming lesion  [7], and can exert both pro- and 
antiatherogenic effects on each of the cellular elements of the vessel wall [11]. 
The ubiquitous monocyte, the precursor of macrophages in all tissues, is present in every 
phase of atherogenesis. Also, it’s when T cells are activated by binding of antigens processed 
and presented by macrophages that the cell activation results in the secretion of cytokines, 
including interferon γ (IFN-γ) and TNF-α and β, that amplifies the inflammatory response. [6]  
The unending entry, the survival, and replication of mononuclear cells in atherosclerotic 
plaques are dependent, in part, on factors such as M-CSF and granulocyte–macrophage colony-
stimulating factor for monocytes and IL-2 for lymphocytes. Continued exposure to M-CSF 
allows macrophages to survive in vitro and possibly to multiply within the atherosclerotic 
plaques in vivo. In contrast, inflammatory cytokines such as IFN-γ activate macrophages and 
under certain circumstances induce them to undergo programmed cell death (apoptosis) [15]. 
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But considering these effects in a global manner it was observed that the presence of M-CSF 
[62], TNF-α and IFN-γ [1, 32] in plaques changes expression of macrophages scavenger 
receptors, that will allow these cells to continually engulf modified lipoproteins leading to their 
accumulation in the cytoplasm until their death [6] and in this way become involved in the 
necrotic cores characteristic of advanced, complicated lesions [15]. 
When considering the role of inflammation in the development and progression of ATH it is 
also important to distinguish between local inflammation, shown in the activation of cells within 
the plaque microenvironment itself, and systemic inflammation, as evidenced by acute-phase 
proteins production and circulating pro-inflammatory mediators. Locally produced 
inflammatory mediators include the products 
of activated macrophages and T cells, such as 
TNF-α, IL-1β, IL-8, IL-18 and MCP-1, all of 
which are produced in response to modified 
forms of LDL and/or bacterial products. 
Systemic mediators and markers of 
inflammation include IL-6, IL-1β and CRP  
[2]. Table II lists some of the cytokines and 
inflammatory mediators that influence the 
development of atherosclerotic lesions in 
animal models of ATH [63]. 
 
2. Oxidative Stress in Atherosclerosis 
In general, initiation and progression of ATH is best explained as an inﬂammatory response 
elicited by retention of lipoproteins in the arterial intima [7]. However, the mechanisms by 
which LDL is oxidized in the arterial wall are still not fully understood, but they might involve 
the cumulative effect of ROS or reactive nitrogen species (RNS) generated by inflammatory 
cells and enzymatic oxidation [64] during the response against the previous referred risk factors. 
For example, when in a hypertensive state the individual experiences a rise in the formation of 
hydrogen peroxide and free radicals such as superoxide anion and hydroxyl radicals in the 
plasma [45, 65]. These substances reduce the formation of nitric oxide (NO) by the endothelium 
[66], increase leukocyte adhesion and peripheral resistance [15]. 
Others authors proposed that the oxidative modification of LDL might be due to the 
existence of catalytically active transition metal ions [64] in the plaque microenvironment. The 
extensive LDL oxidation characteristic of atherosclerotic lesions may require a source of iron 
(Fe) or copper (Cu) as catalyst for the oxidation [67]. In fact, the interior of advanced human 
atherosclerotic plaques is a highly pro-oxidant environment containing redox-active Fe and Cu 
Table II - Summarized list of inflammatory mediators 
involved in atherogenesis (From Greaves & Channon [2]) 
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ions, that in vitro induces lipid peroxidation [68, 69], but as Cu is more potent than Fe in 
catalyzing cellular LDL oxidation [70] it is possible it could account for the initiation of 
oxidation of LDL present in the arterial wall [71]. 
 
2.1 A link between the immune system, iron metabolism and oxidative stress:  
Ceruloplasmin 
Cp is an abundant, blue plasma protein (metalloenzyme) which accounts for 95% of total 
circulating Cu in healthy adults [72]. Cp is a multifunctional protein with several functions that 
may play contradictory roles [73]. In fact, the protein is a multicopper oxidase and it possesses 
both anti-oxidant and pro-oxidant activities. It is also an acute-phase protein involved in the 
inflammatory process [67]. 
As a result of alternative splicing [74] there are two isoforms of Cp, one secreted mainly by 
the liver (sCp) and other anchored to the membrane by a glycosylphosphatidylinositol (GPI) 
group (GPI-Cp) in various cell types [75, 76], including monocytes [77]. Previously, it was 
demonstrated by our research group that GPI-Cp is also expressed in peripheral blood 
lymphocytes (PBL), reinforcing the intimate connection between Cp and the immune system 
[78] and its putative involvement during atherogenesis. 
Cp is able to oxidise different substrates such as biogenic amines, phenols and Fe. On the 
other hand, Cp’s anti-oxidant activity was also reported and it seems that this activity has a 
crucial importance in the inflammatory process and acute phase response [67]. This feature is 
evidenced not only by the capacity of Cp to act as a scavenger of superoxide anion radicals and 
other ROS [79], but also through the inhibition of Fenton reactions, by conversion of Fe
2+
 in to 
Fe
3+
 (a non-toxic form) due to the ferroxidase activity of Cp [67]. This contribution by Cp might 
help activated macrophages to drive Fe out of infected cells [80] and is thought to be an 
important mechanism in host defense by driving Fe homeostasis in a unfavourable way to the 
infectious organism [81]. Furthermore, Cp ferroxidase activity is thought to enhanced Fe efflux, 
by increasing the binding  of  Fe  to  transferrin (Tf),  thus  providing  a negative  Fe  gradient 
from the perspective of the cell [82].  Observations in Cp
-/-
 animals and in human patients with 
hereditary Cp deficiency, also supports this theory as it leads to an accumulation of Fe in the 
spleen, liver, and brain but with an overall systemic iron deficiency [83, 84]. Recently, it was 
reported that multicopper oxidases such as Cp are required for the Fe exporter ferroportin 
stabilization at cell surface, thus promoting cellular Fe efflux [85]. 
However, it is also known that Cp has the ability of oxidizing lipids through pro-oxidant 
activity. Ehrenwald et al. showed that Cp enhanced, rather than suppressed, the oxidation of 
LDL and that this activity was dependent on the integrity of its structure and its bound Cu [86]. 
Oxidative modification of Cp may result in conformational changes that dissociates the Cu 
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bound to Cp, thereby impairing its oxidase activity. In fact, free Cu may in turn promote 
oxidative reactions [87] with potential to cause various pathological effects, such as the decrease 
of NO bioavailability [86], which in turn could be an important factor in CHD since NO is 
responsible for inhibiting proliferation of vascular SMC, adhesion molecules expression and 
lipid oxidation[88]. 
Previous studies showed that levels serum Cp levels increase during pregnancy and in 
several pathological conditions including CVD [67]. Adelstain et al. were the first to correlate 
CVD and Cp by demonstrating that an increase in sCp was detectable after MI [89]. Afterwards, 
Kok et al. observed that individuals with the highest quantity of serum Cu were those who had 
four times higher risk of death from CHD [90]. It was also demonstrated that elevated serum 
LDL was associated with accelerated atherogenesis [91] and that individuals with reduced 
serum HDL had higher incidence of CVD. In this case, the individuals with the highest risk 
were those with low HDL and high Cp levels [92]. Consequently, it is believed that the 
contribution of Cp to the risk of CHD is not independent but rather depends on lipoprotein 
profile and perhaps other factors [93]. 
Regulation of Cp expression has been demonstrated in different cell populations [81, 94, 95]. 
Several cytokines and other factors induce sCp synthesis in hepatic cells, such as IL-1 and IL-6 
[96], TNF-α and lipopolysaccharide (LPS). In cells of myeloid lineage, sCp synthesis was 
successfully induced in vitro by TNF-α in alveolar macrophages [97] and in monocytic cell 
lines by IFN-γ [81]. More recently, di Patti et al. reported the upregulation of Cp expression 
(both in the secreted and GPI-linked forms) by treatment with the pro-inﬂammatory cytokine 
IL-1β in a rat glial cellular model [94]. However, despite all these studies the physiologic 
functions of both Cp isoforms have not been elucidated with certainty.  
Recently, it was shown that Cp and oxLDL colocalize in ATH lesions. Also, it was 
suggested that monocyte-derived macrophages might be the main Cp sources for LDL oxidation 
in the arterial wall, and that localize into the subendothelial space following endothelium 
activation [71].  
In this study, we aim to improve our knowledge of the functional association between 
inflammation, lipid and Fe/Cu metabolism. Particularly, we expect to gain better insight into the 
role of Cp in the pathophysiology of ATH.  
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OBJECTIVES 
The general goal of this thesis is to investigate in vitro and in vivo the underlying 
mechanisms relevant to the functional association of inflammation, lipid and Fe/Cu metabolism, 
in order to achieve a new understanding into the pathophysiology of ATH. 
In order to achieve this main objective we specifically propose to: 
1. Study in peripheral blood mononuclear cells (PBMC) from healthy individuals the 
regulation of cell surface Cp by altered Fe or Cu status, pro-inflammatory cytokines and 
other immunomodulators, and RNS; 
2. Search for a putative association between PBMC surface Cp expression and oxidation 
of LDL; 
3. Perform laboratorial characterization of Familial Hypercholesterolemia (FH) patients, as 
a clinical model of ATH; 
4. Search for biochemical and immunological associations between the parameters 
measured in 3, in order to further understand the interaction of Fe/Cu, lipid metabolism 
and inflammation at systemic level. 
In summary, with this study we expect to gain a better insight into the main mechanisms 
involved in the immune regulation of Fe/Cu metabolism related to the development of ATH, 
both at local and at systemic level. 
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MATERIALS AND METHODS 
1. Population of study 
Forty healthy individuals (27 females, 13 males; mean age 37.55 ± 12.36 years) and 40 FH 
patients (24 females, 16 males; mean age 42.85 ± 16.15 years) were included in the study.  
The recruitment of healthy donors was rigorous and followed the subsequent criteria: 
absence of cardiovascular and lipid disorder; absence of medication and drug use; absence of 
drinking and smoking habits. 
FH disease is one of the most common genetic disorders [98], and manifests itself by high 
levels of total and LDL cholesterol, with normal levels of HDL cholesterol and triglycerides. 
These individuals tend to develop premature ATH and have increased risk of CHD [99]. Serum 
samples from diagnosed FH patients were selected from the Portuguese Familial 
Hypercholesterolemia Study (EPHF) developed at Grupo de Investigação Cardiovascular, 
Unidade de I&D Departamento de Promoção da Saúde e Doenças Crónicas, Instituto Nacional 
de Saúde Doutor Ricardo Jorge (INSA). These individuals also had associated a family history 
of hypercholesterolemia and CVD [54].  
Blood and serum collection took place at INSA after all participants signed an informed 
consent form, approved by the ethical commission of the participating institution.  
 
2. Isolation of peripheral blood mononuclear cells 
Blood from healthy volunteers was collected in citrate CPT™ vacutainer tubes (BD, 
Germany) and PBMC were isolated according to the manufacturer’s protocol. Brieﬂy, tubes 
were centrifuged in the first 2 hours (h) after collection at 2800 rpm for 30 minutes (min) at 
room temperature to separate the PBMC from erythrocytes and granulocytes by the Ficoll 
inserted below a gel layer.  
The resulting mixture of PBMC and plasma was recovered and then cells were pelleted 
(1500 rpm, 10 min). Residual erythrocytes were excluded using a lysis solution (10 min, 37 °C), 
and finally PBMC were washed with PBS.  Assessment of cell viability was performed by 
Trypan blue exclusion method, using a Neubauer chamber before pelleted cells were cultured. 
Aliquots of plasma samples were stored at -80ºC for future laboratorial characterization.  
 
3. In vitro modulation of cell surface ceruloplasmin expression 
After isolation of PBMC from healthy volunteers, the cells were cultured in the 
presence/absence of a specific treatment depending on which condition to be tested, and 
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incubated in triplicates (n=3) at 37 ºC in a humidified incubator with 5% CO2 atmosphere for 
each described time. 
After the incubation period, PBMC were washed and pelleted (1500 rpm, 10 min) from the 
supernatants and ressuspended in Staining Buffer, the appropriate solution for 
immunophenotyping and Flow Cytometry analysis. The supernatants from the cultures were 
collected, alliquoted and stored at −80°C for future Western Blot analysis if needed. 
 
3.1. Iron and copper status 
Several compounds were used in order to increase or remove Fe or Cu ions from medium of 
PBMC culture. Increased Cu status was induced using Cu-Histidine (CuHis), which is a stable 
complex, while Cu depletion was achieved with Bathocuproine disulphonate (BCS), a specific 
Cu chelator. On the other hand, alterations of Fe status were induced on cell culture medium 
using Holotransferrin (Holo-Tf), a high affinity Fe saturated transferrin (responsible by the 
preferential and physiological way of Fe delivery in a wide range of cell types [100]). Also, a 
non-transferrin bound Fe compound was tested, 'free' Fe provided in the form of Fe-
nitrilotriacetate (Fe-NTA, a stable complex). Fe depletion was achieved with Fe(III) chelator 
desferrioxamine (DFO). 
The tested conditions were as follows: 
 
Table III – Iron and copper treatments used to modify Fe/Cu status in 
PBMC culture 
 Concentration tested Incubation time 
Holo-Tf 2,5; 5 mg/mL 20 h 
Fe-NTA 10, 50, 100 µM 18 h 
DFO 10, 50, 100 µM 18 h, 20 h 
CuHis 10, 50, 100 µM 18 h 
BCS 100, 200 µM 18 h 
 
 
 3.2. Cytokines and other immunomodulators 
In order to study the effect of several putative pro-atherogenic stimuli on Cp expression at 
surface of PBMC, IFN-γ, IL-1β, IL-2, IL-6, IL-8, TNF-α (BD Pharmigen, USA) and M-CSF 
(R&D Systems) were used. Also, the inflammatory stimulators phorbol-12-myristate-13-acetate 
(PMA; Sigma-Aldrich, USA) and LPS from Escherichia coli (Sigma-Aldrich, USA) were 
tested. Below are described the conditions used for each treatment: 
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Table IV – Experimental conditions used to test the effect of cytokines and 
other immunomodulators in PBMC culture 
 Concentration tested Incubation time 
IFN-γ 1, 10  ng/mL 1 h, 18 h  
IL-1β 20, 50 ng/mL 18 h 
IL-2 10, 50 ng/mL 18 h 
IL-6 10, 50, 100 ng/mL 18 h 
IL-8 14.3, 71.5, 143 ng/mL 18 h 
TNF-α 2, 12, 20 ng/mL 18 h 
M-CSF 20, 50, 100 ng/mL 20 h 
PMA 5 ng/mL 2 h 
LPS 10, 100 ng/mL 20 h 
 
3.3. Reactive nitrogen species 
In the context of pro-atherogenic conditions present in the microenvironment of 
atherosclerotic plaques, ROS and RNS are very important to establish the pro-oxidant/anti-
oxidant setting encountered at these sites. 
To test the influence of specific RNS conditions on cell surface Cp expression of PBMC, 
cells from healthy donors were cultured overnight in the presence/absence of the NO donor S-
nitroso-N-acetylpenicillamine (SNAP; Invitrogen, USA) at 100 and 500 µM concentrations. 
 
 
4. Immunophenotyping and Flow Cytometry analysis 
After the specific incubations, treated and non-treated PBMC were plated in 96-well round-
bottomed microtiter plates (Nunclon, Denmark) at 5×10
5
 cells/well and incubated for 15 min 
with AB-Human Serum, blocking the Fc-receptor binding sites for reduction of non-specific 
reactions. Afterwards, cells were stained for Cp using the rabbit anti-Human Cp (KOMA 
Biotech, Korea) as primary antibody (Ab) for 45 min, washed once with Staining Buffer and 
spun 250 X g at 4ºC for 5 min. Subsequently the cells were incubated for 45 min with the 
secondary Ab, a goat F(ab′)2 anti-rabbit FITC-conjugated (Rockland, USA) along with 
monoclonal Abs (mAb) CD45-PerCP, CD14-APC, CD3-PE and CD69-PerCP. 
After staining, the cells were washed once with Staining Buffer, spun 250 X g, 4ºC for 5 min 
and ressuspended in the same solution, transferred to cytometer tubes and analyzed in a 
FACSCalibur Flow Cytometer (BD Biosciences, USA). 
To determine Cp mean fluorescence intensity (MFI) in specific cell subsets, fluorochrome-
conjugated mAbs against CD45, CD14, CD3 and CD69 were used. MAb CD45-PerCP allows 
for lymphocyte gating and combined with mAb CD3-PE allows the positive or negative 
selection of T cells. Also, mAb CD45-PerCP with CD14-APC were used for monocyte gating. 
In each case, mAb CD69-PerCP was used to gate activated and non-activated cells. All mAb 
were from BD Pharmigen, USA. Non-treated stained cells were used as negative control, to 
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determine autofluorescence in each assay. CellQuest (BD Biosciences, USA) was used for data 
acquisition, and measurement of Cp expression was performed using Weasel v.2.7.4 software.  
 
5. Quantification of oxidized LDL in cell culture supernatants 
PBMC were isolated from healthy donors and PBMN e PBL were incubated overnight with 
RPMI medium in the presence/absence of 20 ng/mL of IL-1β and human LDL (Sigma-Aldrich, 
USA) reconstituted in nitrogen-saturated solution, to certify the LDL was in its native state and 
minimize its spontaneous oxidative modification not related to the effect of Cp. 
The concentration of oxLDL in the culture supernatants was measured by a sandwich 
Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) (oxLDL ELISA kit, K7810, 
ImmunDiagnostik AG, Germany) according to the kit protocol and measured 
spectrophotometrically with ELISA plate reader Milenia™ Kinetic Analyzer (Diagnostic 
Products Corporation, USA).  
 
6. Laboratorial characterization of Familial Hypercholesterolemic patients: a 
model to study atherosclerosis 
The groups of healthy individuals and FH patients was biochemically characterized through 
the determination of concentration levels of total cholesterol, HDL and LDL cholesterol, 
triglycerides, apolipoprotein A1 (ApoA1), apolipoprotein  B (ApoB), Lipoprotein (a) (Lp(a)), 
Fe, Tf, ferritin, CRP and sCp, which were measured in serum samples (stored at -20ºC). 
Determination of lipid profile was performed by an enzymatic colorimetric method following 
the manufacturer’s instructions in an automated chemistry analyzer (Cobas Integra 400, Roche). 
Determination of CRP, Fe, Ferritin, Tf, sCp levels were executed in the same equipment with 
respective method. All these analysis were performed at Unidade Laboratorial Integrada 
(INSA).  
Additionally, the levels of oxLDL and IL-1β were quantified in serum samples using the 
following immunoenzymatic assays (ELISAs): oxLDL ELISA Kit (ref. K7810, 
ImmunDiagnostik AG, Germany) and BD OptEIA™ ELISA IL-1β Kit (BD, USA) respectively, 
following the manufacturers’ instructions. 
 
 
7. Statistical Analysis 
All data analysis was performed using Microsoft™ Office Excel and SPSS v.17. 
Results from each modulation experiment are presented as means ± Standard deviation in the 
respective figure. After the normality assessment was performed, to compared the means of two 
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related samples Student’s t-test was used. In alternative it was employed the non-parametric test 
Wilcoxon. 
When comparing the two independent samples from FH patients and control group, after 
normality assessment was performed the parametric Student’s t test was employed. In 
alternative, the non-parametric test Mann-Whitney was used. Spearman correlation coefficient 
was used to analyze the relationship between the laboratorial characterization parameters of 
these two groups.  
In all comparisons, the significance level to reject the null hypothesis was 5%, that is, p- 
values < 0.05 were considered statistical signiﬁcant. 
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RESULTS 
1. Ceruloplasmin expression at surface of peripheral blood mononuclear cells 
 Cp is usually described as a multifunctional protein with both anti-oxidant and pro-oxidant 
activities, being of crucial importance during the inflammatory process and acute phase 
response [67]. The intimate connection between Cp and the immune system [78] and possible 
role of Cp during atherogenesis is justified due to its existence in various cell types [76], 
including PBMN [74] and PBL [78]. Thus, in order to understand the possible physiological 
role of Cp expressed at the surface of specific leukocyte populations, this protein expression 
was analyzed at surface of PBMN and PBL isolated from healthy blood donors, using flow 
cytometry analysis. 
 Results obtained after overnight incubation of PBMC with culture medium alone (RPMI-
1640 medium) showed consistently higher cell surface expression of Cp in PBMN compared to 
PBL (Figure 3A) and in activated vs non-activated cells (Figure 3B). Also, analysis of Cp 
expression at surface of PBL subpopulations, showed that non-T cells have higher surface Cp 
expression compared to T cells (Figure 3C). 
 
 
Fig. 3 –Flow Cytometry analysis of surface Cp expression in non-treated PBMC. A) Surface Cp expression 
in PBMN and PBL (n=16); B) Surface Cp expression in PBMN and PBL depending on their activation state 
(n=12); C) Surface Cp expression in PBL subpopulations (n=16), (*p < 0.05, **p < 0.01). 
 
 
 
2. Regulation of surface ceruloplasmin expression by iron and copper status 
 Human atherosclerotic plaques contain elevated levels of both Cu and Fe [68]. In order to 
test if Fe and/or Cu status influence the expression of surface Cp in PBMC, cells were treated in 
presence/absence of these metals under different experimental conditions.  
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2.1. Modulation of iron status  
2.1.1. Holotransferrin 
PBMC incubation with holo-Tf caused a 10% decrease in the percentage of Cp+ PBMN 
(data not shown), while a concomitantly non-statistically significant decrease in Cp surface 
expression was observed on this cells (Figure 4A).  
On the other hand, PBL treated with holo-Tf showed upregulation of surface Cp expression 
in a dose dependent manner, being statistically significant for 5 mg/mL holo-Tf (Figure 4B) due 
to the upregulation of Cp expression in activated cells (Figure 4C). Also, a slight increase in the 
number of activated cells and Cp+ cells was observed in this cellular population (data not 
shown).  
  
  
Fig. 4 - Effect on PBMC surface Cp expression after overnight incubation with Holo-Tf. 
Flow cytometry results of Cp expression at surface of A) PBMN, B) PBL and C) activated and 
non-activated PBL incubated overnight with Holo-Tf (Ctrl: non-treated cells, n=3, *p<0.05). 
 
2.1.2. Iron-NTA 
 As observed in Figure 5, Fe-NTA treatment did not show any significant effect on Cp 
surface expression in PBMN and PBL (Figure 5A and 5B, respectively). In fact, only a trend to 
decrease in Cp expression at surface of PBMN could be observed, particularly at 100 µM Fe-
NTA.  
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Fig. 5 - Effect on PBMC surface Cp expression after overnight incubation with Fe-NTA. 
Results of flow cytometry analysis of surface Cp expression in A) PBMN and B) PBL incubated 
overnight with Fe-NTA (Ctrl: non-treated cells, n=3). 
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2.1.3. Desferrioxamine  
Incubation of PBMC with the Fe chelator DFO showed a trend to an increased surface Cp 
expression in both cell populations analyzed. In PBMN the upregulation of surface Cp 
expression was statistically significant at 100 μM DFO (Figure 6A). 
In PBL, no statistically significant differences were observed between cells treated with DFO 
and non-treated. However, a trend to an increase of surface Cp expression in a dose dependent 
manner was observed (Figure 6B), with a concomitantly increase in the percentage of activated 
and Cp+ cells (data not shown).  
 
   
Fig. 6 - Effect on PBMC surface Cp expression after overnight incubation with DFO. Flow 
cytometry results of Cp expression at surface of A) PBMN and  B) PBL in cell cultures 
incubated overnight with DFO (Ctrl: non-treated cells, n=3, *p<0.05). 
 
 
2.2. Modulation of copper status  
 Modulation of Cu status in vitro did not have any significant effect in surface Cp expression 
both in PBMN (Figure 7A) and PBL (Figure 7B). This finding was also observed in both 
PBMN (Figure 8A) and PBL (Figure 8B) when BCS Cu chelator treatment was tested. 
 
 
  
Fig. 7 - Effect on PBMC surface Cp expression after overnight incubation with CuHis. 
Results of flow cytometry analysis of surface Cp expression in A) PBMN and B) PBL incubated 
overnight with CuHis (Ctrl: non-treated cells, n=3). 
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Fig. 8 - Effect on PBMC surface Cp expression after overnight incubation with BCS. 
Results of flow cytometry analysis of surface Cp expression in A) PBMN and B) PBL incubated 
overnight with BCS (Ctrl: non-treated cells, n=3). 
 
3. Regulation of surface ceruloplasmin expression by cytokines and other 
immunomodulators 
In order to test the hypothesis of Cp immunomodulation by pro-atherogenic stimuli, 
measurement of Cp surface expression of PBMC cultured in the presence of several cytokines 
and immunomodulators putatively associated to atherogenesis, was performed. 
 
3.1. IFN-γ 
IFN-γ is produced locally on atherosclerotic plaques [101] and promotes macrophage and 
EC activation. It also inhibits cell proliferation, collagen production, and cholesterol efﬂux 
[102]. Importantly, IFN-γ has been often considered a major pro-atherogenic cytokine [103]. 
In this study, PBMC incubated for 1 h in culture medium in the presence of IFN-γ showed a 
slight increase of surface Cp in PBMN (Figure 9A) and PBL (Figure 9B). However, these 
differences were not statistically significant.  
 
  
Fig. 9 - Effect on PBMC surface Cp expression after 1h incubation with IFN-γ. Flow 
cytometry results of Cp expression at surface of A) PBMN and B) PBL incubated for 1 h with 
INF-γ (Ctrl: non-treated cells, n=3). 
 
Observing Cp expression at surface of PBMN and PBL depending on their state of activation  
showed that while in PBMN the upregulation of surface Cp expression was due to both 
activated and non-activated cells (Figure 10A), in PBL the upregulation of Cp  is mostly 
associated with activated cells (Figure 10B). 
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Fig. 10 - Effect of IFN-γ on activated and non-activated PBMC surface Cp expression after 1h 
incubation. Flow cytometry results of Cp expression at surface of activated and non-activated A) 
PBMN and  B) PBL after 1 h incubation with INF-γ (Ctrl: non-treated cells, n=3). 
 
On the other hand, in PBMC incubated in the same conditions but for a longer period of time 
(18 h), a decrease of Cp expression at cell surface was observed. Figure 11 shows the decreased 
expression in total PBMN (Figure 11A) and PBL (Figure 11B), being the decreased Cp 
expression in PBL statistically significant for 10 ng/mL (Figure 11B).   
 
   
Fig. 11 - Effect on PBMC surface Cp expression after overnight incubation with IFN-γ. Flow 
cytometry results of Cp expression at surface of A) PBMN and B) PBL incubated overnight with 
INF-γ (Ctrl: non-treated cells, n=3, *p<0.05). 
 
Furthermore, in the presence of IFN-γ PBMN cell activation increased in a dose dependent 
manner (Figure 12A), while the percentage of activated PBL was not largely affected by this 
cytokine (Figure 12B). 
 
  
Fig. 12 - Effect on PBMC cell activation after overnight incubation with IFN-γ. Flow 
cytometry analysis of CD69+ expression at surface of A) PBMN and B) PBL in cell cultures 
incubated overnight with INF-γ (Ctrl: non-treated cells, n=3). 
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3.2. IL-1β 
IL-1β is known as a lymphocyte activating and B-cell differentiation factor [104], but it was 
recently associated with CVD [105] and with ATH progression [106]. In this context, the effect 
of IL-1β on PBMC surface Cp expression was tested. 
When PBMN were incubated with IL-1β at 20 and 50 ng/mL concentrations, an increase of 
surface Cp expression was observed in these cells (Figure 13A). Also, in this cell population, 
the number of activated cells increased with the treatment (data not shown), being surface Cp 
upregulation mostly associated with activated PBMN (Figure 13B). 
 
  
Fig. 13 - Effect on PBMN surface Cp expression after overnight incubation with IL-1β. 
Flow cytometry results of Cp expression at surface of A) PBMN and B) activated and non-
activated PBMN in cell cultures incubated overnight with IL-1β (Ctrl: non-treated cells, n=3, 
*p<0.05) 
 
In total PBL, no significant effect of IL-1β on surface Cp expression was observed when 
comparing treated and non-treated cells (Figure 14A). However, surface Cp expression showed 
a tendency to decrease in a dose-dependent manner when analyzing activated vs non-activated 
PBL (Figure 14B). The percentage of Cp+ PBL was not affected by this interleukin and only a 
minimal increase in cell activation could be observed in PBL (data not shown). Regarding PBL 
subpopulations, a significant decrease of surface Cp expression was observed in non-T cells 
when in the presence of 50 ng/mL IL-1β (Figure 14C). Concomitantly, a small but steady 
increase in the percentage of activated non-T cells was observed along a small but constant 
decline in Cp+ cells was observed (data not shown). 
 
 
   
Fig. 14 - Effect on PBL surface Cp expression after overnight incubation with IL-1β. Flow cytometry results of Cp 
expression at surface of A) PBL, B) PBL depending on their activation state and C) PBL subpopulations incubated 
overnight with IL-1β (Ctrl: non-treated cells, n=3, *p<0.05, **p<0.01). 
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 3.3. IL-2 
IL-2 is a pro-inflammatory cytokine and a recognized growth factor for T and natural killer 
(NK) cells [107]  involved in the proliferation and activation of these cells [108]. Recent studies 
showed serum IL-2 levels to be associated with atherosclerotic processes and a good indicator 
of the likelihood of an acute clinical event [109]. In this context, PBMC from healthy subjects 
were incubated overnight IL-2, to test for a possible modulation of surface Cp expression in 
these cells.  
Our results showed that this treatment caused a progressive but non-statistically significant 
decrease in surface Cp expression in PBMN (Figure 15A). Similar effect could also be observed 
on PBMN regarding their activation state (Figure 15B), with both activated and non-activated 
PBMN showing a decrease of surface Cp expression. Furthermore, this modulation of Cp was 
observed along with a concomitantly decrease of Cp+ cell numbers (data not shown), while the 
percentage of activated PBMN increased slightly in a dose dependent manner (Figure 15C).  
 
   
Fig. 15 - Effect on PBMN surface Cp expression and cellular activation after overnight incubation with IL-2. Flow 
cytometry results of Cp expression at surface of A) PBMN and B) activated and non-activated PBMN; C) Percentage of 
activated PBMN incubated overnight with IL-2 (Ctrl: non-treated cells, n=3, *p<0.05)  
 
 
In PBL, the effects of IL-2 were mainly observed on non-T cells (data not shown), but one 
could notice that this cytokine significantly decreased surface Cp expression in a dose 
dependent manner in total PBL (Figure 16A and 16B). This Cp downregulation was 
concomitant with an increase in the percentage of activated PBL (Figure 16C) along with a 
decrease of the number of Cp+ cells (data not shown).  
Analysis of PBL subpopulations also showed IL-2 significantly decreasing surface Cp 
expression in both T and non-T cells for the highest IL-2 concentration tested (Figure 16D). 
Finally, it was observed that IL-2 induced an increase in the percentage of activated non-T cells 
up to 40% (Figure 16E) whilst reducing by half the percentage of Cp+ cells in this specific 
subpopulation (Figure 16F).   
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Fig. 16 - Effect on PBL surface Cp expression and cellular activation after overnight incubation with IL-2. Flow 
cytometry results of Cp expression at surface of A) PBL, B) activated and non-activated PBL, C) Percentage of activated 
PBL. D) Surface Cp expression in PBL subpopulations, E) percentage of activated non-T cells and F) percentage of Cp 
positive non-T cells incubated overnight with IL-2 (Ctrl: non-treated cells, n=3, *p<0.05) 
 
3.4. IL-6 
IL-6 is a multifunctional cytokine that plays a key role in the regulation of the synthesis of 
acute phase proteins [110] and is a major inducer of the systemic inflammatory response 
syndrome [111] with associated risk of CVD [112].  IL-6 was also observed to be increased in 
atherosclerotic arteries [113].  
In this study, the results obtained showed that incubation with IL-6 did not cause any effects 
in the Cp expression at surface of PBMN and PBL, as can be seen in Figures 17A and 17B. 
Also, no change in the percentage of activated and Cp+ cells was observed after incubation with 
this modulator (data not shown). 
 
  
Fig. 17 - Effect on PBMC surface Cp expression after overnight incubation with IL-6. 
Results of flow cytometry analysis of surface Cp expression in A) PBMN and B) PBL incubated 
overnight with IL-6 (Ctrl: non-treated cells, n=3). 
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3.5. IL-8 
IL-8 is a chemotactic cytokine that is released from stimulated EC [114], and it’s able to 
activate and elicit leukocytes migration [115] (specifically neutrophils [116] and NK cells 
[117]) to sites of tissue injury to initiate local inflammatory response [118]. In this context, IL-8 
could be seen as one of the initiation factors of atherogenesis after the first insults to the 
endothelium.  
In order to test the hypothesis of IL-8 effect in surface Cp expression in PBMC, cells from 
healthy donors were incubated overnight with several concentrations of this interleukin. The 
results obtained showed no effect of IL-8 on surface Cp expression in PBMN in the tested 
conditions (Figure 18A and 18B). Similarly, no significant effect on surface Cp expression in 
total PBL was observed, despite a small decreasing trend (Figure 18C and 18D). Interestingly, 
this decrease on surface Cp expression in non-T cells was statistically significance for 71.5 and 
143 ng/mL concentration of IL-8 (Figure 18E). 
 
  
   
Fig. 18 - Effect on PBMC surface Cp expression after overnight incubation with IL-8. Flow cytometry results of 
Cp expression at surface of A) PBMN, B) activated and non-activated PBMN, C) PBL, D) activated and non-activated 
PBL and in E) PBL subpopulations incubated overnight with IL-8 (Ctrl: non-treated cells, n=3, *p<0.05). 
 
 
3.6. M-CSF 
M-CSF is described as a very important immunomodulator in innate immunity and 
inﬂammatory diseases [119]. It is synthesized by a variety of cell types, including EC. It is also 
able to promote survival, proliferation, and differentiation of mononuclear phagocyte lineages 
[119, 120]. In the atheroma formation, M-CSF is responsible for the differentiation of infiltrated 
monocytes into macrophages [121] and has been associated with upregulation of innate 
immunity mechanisms, including scavenger receptors and toll-like receptors [122].  
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In this context, we tested the effect of M-CSF on PBMC surface Cp expression. The results 
obtained showed no significant differences between treated and non-treated cells. One should 
however note that subtancial standard deviations were observed for both PBMN (Figures 19A) 
and PBL (Figures 19B).  
 
   
Fig. 19 - Effect on PBMC surface Cp expression after overnight incubation with M-CSF. 
Flow cytometry results of Cp expression at surface of A) PBMN and B) PBL incubated 
overnight with M-CSF (Ctrl: non-treated cells, n=3, *p<0.05). 
 
3.7. TNF-α 
TNF-α is a pleiotropic pro-inflammatory cytokine that is produced by 
monocytes/macrophages and other cell types, including Th1 cells and NK cells. This cytokine is 
involved in a wide variety of immunological events, playing a key role in inflammation and is 
associated with the pathogenesis of ATH. In fact, TNF-α was recently shown to be involved in 
CVD susceptibility and progression, while its inhibition was associated with reduced ATH 
[123-125]. 
In this context, PBMC from healthy donors were treated with TNF-α overnight. The results 
obtained showed a trend to a progressive decrease of surface Cp expression in PBMN (Figure 
20A) and PBL (Figure 20B). However, the differences between treated and non-treated cells 
were not statistically significant for both cases.  
 
  
Fig. 20 - Effect on PBMC surface Cp expression after overnight incubation with TNF-α. Flow cytometry results 
of Cp expression at surface of A) PBMN and B) PBL incubated overnight with TNF-α (Ctrl: non-treated cells, n=3). 
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3.8. LPS 
As a classical endotoxin, LPS promotes an acute pro-inflammatory state, and in 
macrophages and B cells leads to secretion of various pro-inflammatory cytokines [126].  
Incubation of PBMC with LPS for 20 h upregulated the expression of Cp at surface of 
PBMN (Figures 21A and 21B) while a trend to decreased surface Cp expression was observed 
for PBL (Figures 21C and 21D). These effects of LPS on Cp expression in PBMN and PBL 
were not statistically significant. 
In addition, an increase of activated cells number was observed in both PBMN and PBL in 
the presence of this modulator (data not shown). Furthermore, non-T cells were the main 
subpopulation associated to this increase in activated cells (Figure 21E) as well as to the 
downregulation of surface Cp expression in total PBL (Figure 21F). On the other hand, non-
activated non-T cells showed a slight and non-statistical significant upregulation of surface Cp 
expression in the same conditions (Figure 21F).  
 
  
  
       
Fig. 21 - Effect on PBMC surface Cp expression and cellular activation after overnight incubation with 
LPS. Flow cytometry results of Cp expression at surface of A) PBMN and B) activated and non-activated PBMN, 
C) PBL and D) activated and non-activated PBL; E) Percentage of activated PBL non-T cells and F) surface Cp 
expression of activated and non-activated non-T cells in PBMC culture incubated overnight with LPS (Ctrl: non-
treated cells, n=3, *p<0.05). 
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3.9. PMA 
PMA treatment is often employed in biomedical research as a way to induce immunologic 
activation in cell populations. As the previous results showed, activated PBMC express higher 
amounts of surface Cp compared to non-activated cells. In this context, the effect of this 
activatior on surface Cp expression in PBMC was tested. 
Treatment of PBMC with 5 ng/mL of PMA for 2 h induced cell surface Cp expression in 
PBMN (Figure 22A). Also, activated PBMN were found to express significantly higher levels 
of surface Cp compared to non-activated cells in culture (Figure 22B). The effect of PMA on 
PBL caused a 40% increase of activated cells in culture (data not shown), but cell surface Cp 
expression showed a significant decrease compared to the non-treated cells (Figures 22C and 
22D). In each of PBL subpopulations, the same trend could be observed but none of the effects 
showed to be statistically significant. 
 
  
  
Fig. 22 - Effect on PBMC surface Cp expression after 2 h incubation with PMA. 
Flow cytometry results of Cp expression at surface of A) PBMN and B) PBMN 
depending on their activation state, C) PBL and D) PBL depending on their activation 
state incubated for 2 h with PMA (Ctrl: non-treated cells, n=3, *p=0.05, **p<0.01). 
   
4. Regulation of surface ceruloplasmin expression by reactive nitrogen species  
NO is a relatively stable radical, however, when it reacts with superoxide (a common form of 
ROS generated during oxidative stress conditions, such as inflammation) generates 
peroxynitrite, a powerful oxidizing intermediate [71]. Immunohistochemical studies showed 
elevated levels of RNS in human atherosclerotic lesions [74, 80], suggesting that these may 
promote LDL oxidation in vivo [127, 128]. 
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SNAP, a speciﬁc donor of NO, caused a significant increase of surface Cp expression in 
PBMN at concentration of 100 µM (Figure 23A). Also, a 2-fold increase in the percentage of 
activated PBMN was observed when in the presence of this compound (Figure 23B). This effect 
occurred concomitantly with a mild increase of the percentage of Cp+ PBMN (data not shown). 
 
  
Fig. 23 - Effect on PBMN surface Cp expression after overnight incubation with SNAP. 
Flow cytometry results of Cp expression at surface of A) PBMN and B) PBMN depending on 
their activation state incubated overnight with SNAP (Ctrl: non-treated cells, n=3, *p<0.05). 
 
When PBMN were incubated under the influence of both SNAP and IL-1β a slight 
synergistic effect on surface Cp expression could be observed. In fact, surface Cp expression in 
co-stimulated PBMN was higher than in non-treated PBMN or treated with only one of these 
modulators (Figure 24). However, the resulting co-stimulation surface Cp expression was 
shown to be statistically significant only when compared to surface Cp expression of PBMN 
treated with IL-1β alone.  
 
  
Fig. 24 - Effect on PBMN surface Cp expression after overnight incubation with Il-1β and 
SNAP. Results of flow cytometry analysis of surface Cp expression in PBMN incubated 
overnight with SNAP or IL-1β only, and IL-1β+SNAP (Ctrl: non-treated cells, n=3, *p<0.05). 
 
In the case of PBL, SNAP did not induce any significant variations on Cp expression. A 
slight increase of Cp expression at surface of PBL was observed when treated with SNAP only 
(Figure 25A). However, in these conditions the percentage of activated and Cp+ cells did not 
change significantly (data not shown). Conversely, PBL co-stimulated by SNAP and IL-1β 
showed a lower yet (non-statistically significant) surface Cp expression than the one detected in 
non-treated cells and in cells incubated with only SNAP (Figure 25A and 25B). 
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Fig. 25 - Effect on PBL surface Cp expression after overnight incubation with SNAP. Flow 
cytometry results of Cp expression at surface of A) PBL and B) aPBL depending on their 
activation state incubated overnight with SNAP and IL-1β+SNAP (Ctrl: non-treated cells, n=3, 
*p<0.05). 
 
 
5. Study of putative association of GPI-Cp expression and LDL oxidation 
The cell culture supernatants of PBMN and PBL overnight culture in the presence of IL-1β 
and native LDL were assayed in duplicate as described in Materials and Methods section.  
Concentrated aliquots of supernatants were still under the range of detection of oxLDL kit for 
most of the samples. The only samples in which oxLDL levels were detected were the ones 
where cells were incubated with IL-1β: in two conditions of PBMN incubated with native LDL 
and IL-1β, with an average concentration of 3.65 ng/mL of oxLDL. 
 
 
6. Biochemical and immunologic characterization of FH patients as a model to 
study atherosclerosis 
Serum samples of a total of 80 subjects were used for this study and constituted by two 
separate groups: the control group of 40 healthy individuals and the FH group comprised of 40 
FH patients. All clinical, biochemical and immunologic data obtained from all these individuals 
is summarized in Table V. Descriptive and inference statistics were performed as described in 
section 7 of Materials and Methods section.  
When comparing the Control group with FH group, significant differences could be observed 
in total cholesterol, LDL, triglycerides, ApoB and Lp(a). Immunological and Fe status 
parameters did not present statistically significant differences between these two groups, 
although ferritin, oxLDL and IL-1β showed increased levels in FH patients. The biochemical 
and immunologic parameters are summarized in Table V. 
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Table V - Biochemical and immunologic characterization of controls and FH patients. P values 
were indicated for statistically significant results, ns not statistically significant. 
Parameters 
Control FH 
p-value 
n mean ± SD n mean ± SD 
Age (years) 40 37,55 ±12,36 40 42,85 ±16,15 
 Female (%) 27 67,5 24 60,0 
 Male (%) 13 32,5 16 40,0 
 Total cholesterol (mg/dL)** 40 184,26 ± 30,04 40 258,43 ± 74,82 <0,001 
HDL (mg/dL)** 40 56,18 ± 18,25 40 51,02 ± 15,78 ns 
LDL (mg/dL)* 40 109,35 ± 21,19 40 186,15 ±69,70 <0,001 
Triglycerides (mg/dL)** 40 101,03  ± 58,39 40 120,80  ± 50,98 0,027 
ApoA1 (mg/dL)** 40 163,40 ± 40,28 40 156,43 ± 36,98 ns 
ApoB (mg/dL)* 40 70,58 ± 12,55 40 111,60  ± 36,62 <0,001 
Lp(a) (mg/dL)** 40 22,10 ± 19,39 40 57,65 ± 62,78 0,03 
Iron (μg/dL)* 40 93,50 ± 34,08 40 91,50 ± 34,75 ns 
Transferrin (mg/dL)* 40 284,15 ± 46,82 40 280,73 ± 56,53 ns 
Ferritin (ng/dL)** 40 107,13 ± 106,61 40 131,36 ± 112,01 ns 
CRP (mg/dL)** 40 0,36 ± 0,41 40 0,27 ± 0,30 ns 
sCp (mg/dL)** 40 28,26 ± 9,06 40 26,67 ± 9,23 ns 
oxLDL (ng/dL)** 40 118,83 ± 116,76 40 154,78 ± 131,06 ns 
IL-1β (pg/dL)** 40 1,26 ± 1,19 40 4,00 ± 4,06 ns 
*t Student test 
    **Mann-Whitney test 
ns – non-significant 
     
 
In order to search for possible correlations between the parameters 
measured, Spearman correlation coefficient was used. In the context of the current study, the 
significant correlations found in FH patients related to Fe/Cu, lipid metabolism and 
immunity/inflammation were: sCp negatively correlated with ferritin, and positively correlated 
with CRP and oxLDL. IL-1β was found to be positively correlated with total cholesterol and 
ApoB. These significant correlations are summarized in Table VI. 
 
 
Table VI – Significant correlations of serum Cp or IL-1β with biochemical parameters measured 
in FH patients (n=40) 
Parameter versus r p 
sCp Ferritin - 0,359 < 0,05 
  CRP 0,375 < 0,05 
  oxLDL 0,520 = 0,001 
IL-1β Total cholesterol 0,331 < 0,05 
  ApoB 0,345 < 0,05 
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DISCUSSION 
Several studies have been conducted in order to evaluate the impact of inflammatory factors, 
Fe/Cu status and oxidative stress in the development of ATH. The role of the circulating sCp 
isoform in this process has been addressed, but few studies pondered the putative importance of 
the membrane bound form of this protein (GPI-Cp) that appears to possess a more ubiquitous 
distribution [129] and is expressed in cells actively present in atherosclerotic plaque, such as 
PBL [78] and PBMN [77]. 
In order to study the underlying mechanisms relevant to the functional association of 
inflammation, lipid and Fe/Cu metabolism in ATH, one of the specific objectives of this study 
was to investigate the modulation of cell surface Cp in PBMC by putative pro-atherogenic 
stimuli. Herein, quantification of Cp expression at surface of PBMC was performed by flow 
cytometry, which allowed the measurement of this protein specifically in these two specific 
leukocyte subpopulations: PBMN and PBL. The obtained results showed consistently that 
PBMN express higher surface Cp compared to PBL. Also, analysis of T and non-T cells 
subpopulations showed that the highest surface Cp expression was observed in non-T cells, in 
concordance with previous observations [78, 130]. Furthermore, both activated PBMN and 
PBL, which are frequent in atherosclerotic plaques [6], showed a significantly higher surface Cp 
expression than non-activated cells. These results suggest that similarly to sCp, GPI-Cp may 
have a role in inflammatory response, since its expression was increased in activated cells and 
particularly in cell populations associated with innate immunity. 
On the other hand, increasing evidence has pointed out the pathogenic roles of Fe during the 
development of ATH. In fact, Fe is present in atherosclerotic plaque at concentrations that 
substantially exceed those found in healthy arterial tissue, not being considered an inert 
component of plaque [68], part of the Fe accumulated is redox active and another portion 
remains as reservoir within lesions associated to specific proteins, such as ferritin and 
hemoglobin, but can potentially become reactive [131]. Cp has an essential role in Fe 
metabolism and, as a major ferroxidase in plasma, is required to catalyze the conversion of Fe
2+
 
to Fe
3+
 for binding to Tf, the plasma Fe transporter [82]. Osaki et al. proposed that Fe released 
from cells in ferrous form was oxidized by Cp and bound to apo-Tf, creating a negative 
concentration gradient and thereby stimulating cellular Fe release [132].  
In the current study, incubation with holo-Tf produced opposite effects on the two cell 
populations studied. Cp expression at surface of PBMN was decreased in the presence of holo-
Tf compared to non-treated PBMN. In PBL, a significantly increase of Cp expression mostly 
due to non-activated PBL was observed. However, in activated PBL a trend to decrease of GPI-
Cp expression was observed. These observations suggest that GPI-Cp expression is differently 
regulated by holo-Tf in both PBMN and PBL populations. Also, these differences might be due 
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to different physiological mechanisms of Fe management in these two types of cells. 
Monocytes/macrophages play an important role in Fe homeostasis, storing excess Fe in normal 
conditions and, during inflammatory response, these cells are responsible for restriction of Fe 
availability to local pathogens [133]. On the other hand, only recently was reported the 
expression of hepcidin (the most important protein in the regulation of Fe levels in the body 
[134]) in activated PBL [135]. Abrogation of hepcidin by siRNA unexpectedly significantly 
diminished lymphocyte proliferation. In this context, the decreased expression of surface Cp 
expression observed in PBMN, suggests that in the present experimental conditions PBMN 
might store the available Fe, through inhibition of Fe export and ferroxidase activity of Cp. 
Moreover, activated and non-activated PBL showed opposite trends of surface Cp expression in 
response to Fe treatment. Activated PBL showed decreased surface Cp expression, which 
supports the requirement of Fe for proliferation reported by Pinto et al. [135]. On the contrary, 
the increase of surface Cp expression of non-activated PBL in the presence of holo-Tf suggests 
these cells have a tendency to promote the ferroxidase activity of Cp and/or Fe release. 
Incubation with Fe-NTA, a Fe compound more readily involved in Fe-driven redox reactions 
[136], did not produced any significant effects on Cp expression at surface of both PBMN and 
PBL. In fact, only a non-statistically significant decrease of this protein could be observed for 
PBMN. This appears to be in consensus with the results obtained during holo-Tf treatments, at 
least concerning PBMN surface Cp expression. The majority of PBMN in this culture were 
activated (data not shown), and under Fe overload conditions, results suggest that activated 
PBMN tend to promote Fe storage by inhibiting Fe release. Thus, in this context, diminished Cp 
expression could be one of the mechanisms involved. Previous reports support this hypothesis 
showing that incubation with Fe-NTA completely blocked Fe release in U937 cells [137]. Also, 
in C6 glioma cells, Fe overload induced by ferric chloride treatment showed no difference in 
expression of GPI-Cp mRNA, but induced a significant decrease in GPI-Cp protein [138]. On 
the contrary, the observation that this Fe loading treatment did not modulate surface Cp 
expression in PBL, suggests that these two different Fe sources, Tf-bound Fe (holo-Tf) or non-
Tf-bound Fe, may underline a different regulation mechanism in these cells.  
Decreased Fe status induced by Fe chelator DFO was previously reported to significantly 
increase GPI-Cp protein in C6 glioma cells by a translational regulation mechanism [138]. 
Sarkar et al. observed that in monocytic cell line U937 incubation with DFO markedly 
stimulated Fe release, in which all of the previous loaded Fe was removed within 15 minutes. 
These authors suggested that the development of a negative Fe gradient is an essential 
mechanism for Fe release from these cells [137]. In the present study, the observed results were 
consistent with these previous reports, since PBMC treated with Fe chelator DFO showed a 
higher percentage of Cp+ cells with a concomitant upregulation of surface Cp expression in a 
dose dependent manner in both PBMN and PBL. Thus, one can hypothesize that in conditions 
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of Fe deficiency, cells may promote intracellular Fe efflux by upregulation of surface Cp 
expression. These results may also be explained by the fact that DFO is an inducer of hypoxia-
inducible factor (HIF)-1α, since Fe is required for constitutive HIF degradation [139]. Cp was 
the first positive acute phase protein reported to be regulated by HIF-1 activation [140]. In this 
context, the upregulation of surface Cp expression in PBMC treated with DFO could be 
explained by the non-degradation of HIF-1 and subsequent induction of Cp expression. This 
mechanism of Cp upregulation by HIF-1 could be very important in various pathologies, such as 
hypercholesterolemia and ATH, in which increased levels of HIF-1α in the atheroma plaque 
have been reported due to the hypoxic microenvironment in the plaque [13]. Also, oxLDL is 
itself an inducer of HIF-1α accumulation and activation in human macrophages [141]. This 
mechanism may be contributing for the consistent association of Cp levels with ATH and its 
localization in atherosclerotic plaques. Previous studies have indeed reported the existence of Fe 
[68] and Cp [71] accumulation in atherosclerotic plaques. However, in this study we observe 
that the increase of Fe status in PBMC cultures is followed in general by a tendency to decrease 
GPI-Cp expression in these cells. These observations indicate that Cp accumulation reported in 
atheromas may be resultant of HIF-1 activation due to hypoxic conditions or increasing levels of 
oxLDL in the plaque microenvironment other than to a putative Fe status regulatory mechanism 
of Cp expression. 
Other metals are known to play important roles in vascular inflammation, such as Cu [67]. 
The most thorough data regarding how Cu status may affect Cp expression is related to sCp, 
partly due to its discovery decades before GPI-Cp [142]. Earlier studies, associated Cu 
deﬁciency with lower plasma Cp protein, as a consequence of Cu incorporation failure during 
its synthesis, resulting in the secretion of an unstable apo-Cp that is devoid of ferroxidase 
activity [143, 144] and with a half-life (5 h) considerably reduced when compared with holo-Cp 
form (5 days) [145]. Similarly, the influence of Cu limitations on GPI-Cp was recently studied 
and showed the rapid loss of GPI-Cp protein in spleen and, to a lesser extent in liver, of Cu 
deficient rats, which was observed with no reduction in GPI-Cp mRNA level [146] supporting 
that GPI-Cp apo-protein must present the same instability as the sCp apo-protein. Recently, it 
was also reported that treatment with Cu chelator tetrathiomolybdate consistently reduced sCp 
levels. The effect of this treatment also inhibited LPS-induced inflammatory responses in aorta 
and other tissues of mice, by inhibition of gene transcription of VCAM-1, ICAM-1, MCP-1, IL-
6 and TNF-α, all of which related with vascular inflammation and ATH, suggesting that Cu 
lowering strategies could be of therapeutic value in ATH [147]. However, in the current study, 
alteration of Cu status did not cause any significant effects on surface Cp expression with either 
treatments of CuHis or BCS Cu chelator. These results may be explained by the fact that 
contrary to observations made by in vivo studies, the incubation period tested in our experiments 
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might not have been sufficient to allow the effects of Cp stability to be reflected on PBMC GPI-
Cp expression. 
Several inflammatory cytokines have been implicated in the pathogenesis of ATH. In this 
context, several pro-atherogenic cytokines and immunomodulators were incubated with human 
PBMC in order to study its effects on surface Cp expression. 
Mazumder et al. reported for the first time that IFN-γ stimulated sCp production in 
monocytic cell line [81]. Later, it was also observed that induction of sCp in these conditions 
was subjected to translational silencing after 16 h incubation [148] by a structural element in the 
3’-UTR of the Cp transcript [149] and that, similarly to sCp, a second monocytic Cp transcript 
was regulated in the same way [148]. Herein, distinct results of surface Cp expression after 
incubation with IFN-γ in the two tested conditions (1 h or overnight incubation) were observed. 
After 1 h incubation, a non-statistically significant increase of Cp expression was observed at 
the surface of both PBMN and PBL. In contrast, when PBMC were subjected to 18 h treatment 
with IFN-γ a decrease of surface Cp expression was observed (statistically significant in PBL). 
As previously reported, Cp protein synthesis ceases after 16 h by a mechanism of transcript-
specific translational silencing. Nevertheless, the downregulation of surface Cp expression 
observed in this study could not to be explained by this mechanism. However, this significant 
decrease could be a result of Cp levels returning to its basal expression in order to inhibit 
deleterious effects of excessive Cp, after its maximum levels were reached possibly between 1 h 
and 16 h after stimulation by IFN-γ.  
The multifunctional and pro-inflammatory cytokine IL-1 aﬀects nearly every cell type, often 
in concert with other cytokines or other mediators [150]. IL-1β is of central importance in the 
development of diseases but also in normal homeostasis such as metabolism, hematopoiesis, 
renal and hepatic function [151, 152]. It was also one of the first cytokines to be considered 
instrumental in the propagation of vessel wall inflammation during atherogenesis, due to its role 
in the formation of early lesions [153, 154], maintenance of an inflammatory state [155, 156] 
and involvement in advanced plaque formation. Furthermore, its involvement in the 
destabilization and plaque rupture was reported [157]. These features are further supported by 
the observation that IL-1β serum levels are associated with a history of dyslipidemia and 
unstable angina [105] as well the the protective effect of IL-1β deficiency in ATH severity 
observed in apoE deficient mice [106].  Also, several IL-1β gene polymorphisms have been 
found to be associated with MI [158]. IL-1β was previously reported to induce Cp mRNA in 
hepatocytes [159] and secretion of sCp in astrocytes [160]. Later, di Patti et al. showed that IL-
1β was able to induce GPI-Cp and ferroportin mRNA expression in glial cells, increasing Fe 
efflux in these cells in culture [94].  
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In the present study, PBMN treated with IL-1β showed a statistically significant upregulation 
of surface Cp expression, while in activated PBL and non-T cells a progressive decrease 
dependent on IL-1β concentration was observed. These results show that IL-1β has opposite 
effects on surface Cp expression in both PBMN and PBL, which may be related with specific 
physiological roles and regulation mechanisms of these cell types during the inflammatory 
response. The priority of activated PBL response in inflammatory conditions is to proliferate 
and, as stated before, these cells require Fe to do so. Thus, one can suggest that in these 
conditions Fe export could be inhibited in activated PBL and GPI-Cp diminished expression 
could be a consequence or a means to that inhibition, with shedding of GPI-Cp being a possible 
mechanism. On the other hand, the significant Cp upregulation observed in PBMN might be a 
result of Cp being an acute phase protein and its bactericidal activity induced by inflammatory 
status. 
Previously, it was shown the incubation with pro-inﬂammatory cytokine IL-2 (produced 
largely by stimulated CD4 T cells and pro-inﬂammatory Th1 cells) further stimulates the cell 
growth and differentiation of PBL [53, 109]. Recent data from Elkind et al. also showed that 
serum levels of IL-2 were strongly associated with carotid artery intima-media thickness (a 
predictor of stroke and vascular disease) in a population with asymptomatic or subclinical state 
of ATH. These authors suggested that IL-2 may provide a better index of earlier atherosclerotic 
processes, while other commonly used markers - such as CRP - provide a better measure of later 
processes and the likelihood of an acute clinical event [109]. Herein, the treatment of PBMC 
with IL-2 resulted in a non-statistical significant decrease of surface Cp expression in PBMN, 
concomitant with a slight increase of activated cells. In PBL, this cytokine significantly 
decreased total PBL surface Cp expression in a dose dependent manner, while increasing the 
percentage of activated PBL. Also, it was observed that IL-2 activated a larger amount of non-T 
cells than T cells, whilst significantly decreasing their Cp expression. These results suggest that 
PBMC GPI-Cp may not be a contributing factor during the initial phase of atherogenesis in 
which IL-2 would be involved, particularly in activated PBL where the decreased GPI-Cp 
expression corroborates the hypothesis of inhibition of Fe efflux to promote their proliferation 
after inflammatory stimulation [135]. It would be important to evaluate the effects of IL-2 in 
shorter incubation periods, because similarly to what occurred with IFN-γ treatment, the present 
experimental conditions may not be ideal to detect faster cellular responses in Cp expression.  
On the other hand, IL-6, a classical acute phase cytokine and a recognized pro-atherogenic 
factor secreted by T cells and macrophages to stimulate immune response [161], could represent 
an important mediator of surface Cp expression in PBMC during atherogenesis. However, in the 
present study it was observed IL-6 did not modulate surface Cp expression in both cell 
populations tested. This observation does not corroborate previous studies where was reported 
IL-6 increased levels of sCp protein in hepatoma cell line Hep3B [162] and had little effect on 
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sCp mRNA in HepG2 cell line [159]. However, it is in consonance with other report in 
monocytic cell line U937 treated for 24 h with IL-6 [81]. These results suggest that while no 
effect on surface Cp expression was observed after an overnight incubation with IL-6, it does 
not refute the possibility of IL-6 modulating Cp expression earlier during this treatment. Indeed, 
a possible increase in Cp expression at PBMC surface may have not been detected at the 
experimental conditions used during this study. In fact, Daffada et al. had previously reported 
that the peak of Cp mRNA in stimulated HepG2 occurred 4 to 8 h post-stimulation [159]. Thus, 
shorter incubation periods should be attempted in future studies in order to address the putative 
immediate effects of IL-6 in GPI-CP expression. 
The influence of IL-8 on Cp expression at surface of PBMC was also tested. Since it is also 
considered a pro-atherogenic factor  [161] locally produced in atherosclerotic plaques, and 
being a chemotactic cytokine [2], it was hypothesized this modulator could constitute a key 
initiation factor and/or be able to amplify the inflammatory response during atherogenesis. 
However, IL-8 had no effect on Cp expression at surface of PBMN. In total PBL, a non-
statistically significant decrease in Cp expression dependent on IL-8 concentration was 
observed, while in non-T cells the decrease was statistically significant for the highest IL-8 
concentration tested. These results suggest that similarly with other pro-inflammatory cytokines 
tested, the observable decrease in Cp expression might be a consequence of PBL proliferation 
after activation. In this case only non-T cells, which include NK cells, were observed to be 
significantly stimulated by IL-8, as expected [117]. The fact that IL-8 effect was only 
statistically significant at high concentrations is suggestive of non-T cells involvement in 
atherogenesis when such conditions are encountered in plaque microenvironment. 
On the other hand, surface Cp expression in PBMC after M-CSF treatment was not 
significantly modulated. Technical alterations to the protocol may have hampered the collection 
of results, as the recovered cells were in much less quantity than in all other experiments (only 
10%). Also, a non-specific interaction with platelets in culture could be occurring because 
during data acquisition, a percentage of unspecific cellular components could be observed in the 
plot. Indeed, the PBMC separation protocol does not eliminate platelets completely from the 
sample, and this particular chemokine promotes platelet adherence and platelet activation [163]. 
TNF-α, one of the markers of inﬂammation that is variably expressed in situ in vulnerable 
and unstable plaques [123] has been previously described as an inducer of hepatic Cp synthesis 
[97]. Considering the role of this immunomodulator on Fe metabolism (decreases Fe release, 
while increasing Fe uptake and storage within ferritin in monocyte/macrophages [164, 165]) and 
its direct influence in Fe-mediated ROS production [166], it was anticipated that TNF-α could 
be a modulator of Cp expression. However, TNF-α treatment did not show any significant effect 
on surface Cp expression in both PBMN and PBL. This result may indicate that similarly with 
some of our previous results, the inexistence of Cp modulation in the present experimental 
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conditions may be explained by a limitation to measure Cp expression at surface of PBMC at 
the proper time, observing only the basal Cp expression of these cells. Thus, in order to test this 
hypothesis shorter incubation periods should be performed in future experimental designs to be 
tested. 
Moreover, LPS - a known exogenous pyrogen that promotes an acute pro-inflammatory state 
with the consequential secretion of pro-inflammatory cytokines by many cell types (especially 
in macrophages and B cells) [126] - was tested as putative modulator of surface Cp expression 
in PBMC. As Cp is also an acute phase protein [95], it was expected the increase of sCp 
expression reported by Fleming et al. when different rat tissues were submitted to a dose of LPS 
endotoxin. The authors observed an increased content of sCp mRNA in the liver and also in the 
lung (specifically in alveolar macrophages) and, as sCp mRNA was not consistently detected in 
other extrahepatic tissues, it was concluded that the endotoxin effect was tissue specific [97]. In 
the present study, it was observed that incubation with LPS also modulated surface Cp 
expression in PBMC. In the case of PBMN, in spite of considerable Cp upregulation observed, 
the variation was not statistical significant, which could be an artifact of small sample size. 
However, this observation suggest that similarly to sCp, PBMN surface Cp might play a role in 
host defenses during acute phase responses, through bactericidal and ferroxidase activity. 
Studies showing that hepcidin synthesis in macrophages is upregulated in response to LPS, and 
inflammation [134] resulting in the downregulation of ferroportin and subsequently macrophage 
retention of intracellular Fe [167], support that the increase of surface Cp observed in this 
condition might be more related with its bactericidal activity than to enable Fe efflux. Inversely, 
LPS treatment in PBL increased activated cells in the population with a concomitant trend to 
non-statistically significant decrease of surface Cp expression dependent on concentration of 
LPS. Again, this observation on activated PBL may be a consequence of their Fe-dependent 
proliferation, in which PBL inhibit Fe efflux in order to promote their proliferative activity after 
stimulation. Such observation was also seen in previous treatments with other pro-inflammatory 
cytokines that induced PBL activation, reinforcing the hypothesis of inhibited Fe efflux and 
subsequent diminished Cp expression levels in order to favor activated PBL proliferation. A 
possible mechanism for diminishing GPI-Cp levels at cell surface could be by protein shedding, 
in order to quickly respond to such stimuli. However, measurement of this protein in the 
extracellular medium could not be performed due to time constraints, but it should be assessed 
in the near future to explore this hypothesis. Another interesting observation made during this 
treatment was that non-activated non-T cells actually show increased surface Cp expression 
compared to their activated counterparts. Despite the fact that this result lacks statistical 
significance, further investigations should be performed in order to understand the significance 
of this observation, and if implies different regulation of Fe content in these cells or another role 
altogether.  
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On the other hand, treatment of PBMC with PMA for 2 h showed very similar effects to the 
ones observed for LPS treatment. A statistically significant induction of surface Cp expression 
in response to PMA was observed for PBMN, while in PBL a significant decrease in their 
surface Cp expression was found. The same hypothesis regarding the functional role of surface 
Cp in both populations after incubation with LPS can be suggested here. In fact, similarly the 
current knowledge allows to hypothesize that increased Cp levels in PBMN might be related to 
its bactericidal activity as an acute phase protein, while in PBL the decrease in Cp expression 
could be caused by the need of these activated cells to proliferate and thus their need to inhibit 
Fe efflux from intracellular stores. In order to investigate such hypothesis, in future experiments 
Fe efflux/influx should be also measured in these cell cultures, and further analysis of culture 
supernatants should be crucial to demonstrate if protein shedding is involved in the rapid and 
significant downregulation of PBL GPI-Cp. 
Given the previous reports of RNS involvement in ATH, the putative effect of this 
compounds in surface Cp expression was also tested. In fact, NO released by functional EC of 
the artery wall [168] is critical in vascular homeostasis [169] playing in overall, a protective role 
[170]. In spite of NO being a relatively stable radical, it reacts with locally produced ROS 
during the increasing oxidative stress generated in plaque microenvironment, especially with 
superoxide, to form peroxynitrite [171]. Peroxynitrite is a highly cytotoxic form of RNS [172], 
and has been observed in many inﬂammatory diseases, where it showed  the ability of directly 
or via its reaction products, oxidize LDL and modify other proteins, as well releasing Cu ions by 
destroying Cp [173]. In the present study, RNS putative influence in surface Cp expression was 
tested by incubating PBMC with SNAP, a speciﬁc NO donor after which NO is readily 
oxidized. This treatment caused a significant increase of surface Cp expression in PBMN and 
doubled the percentage of activated cells, while in PBL no significant changes were observed. 
This observation suggests that oxidative stress generated by SNAP supports the previous 
hypothesis that Cp at surface of PBMN might have a more active role in extreme conditions as 
an acute phase protein, or in this case as anti-oxidant compound, compared to Cp expressed by 
PBL. The effect of SNAP on releasing Cu ions from holo-Cp was not directly addressed and the 
expected Cp downregulation by diminished stability of apo-Cp was not observed but, as 
previously discussed in BCS treatment, the incubation period tested here may have not been 
sufficient to detect the instability effect of apo-Cp on Cp expression levels. Also, when PBMN 
were co-incubated with SNAP and IL-1β, a synergistic effect could be observed, as 
inflammatory state and oxidative stress was induced. In PBL, the observed effect by this co-
stimulation was probably attributable solely to IL-1β, as the overall response was similar to IL-
1β treatment in PBL.  
Afterwards, the putative association between PBMC surface Cp expression and oxidation of 
LDL was investigated. Thus, PBMN and PBL cultures were performed in medium 
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supplemented with native LDL and IL-1β. However, technical constraints hampered the 
detection of oxLDL levels in almost all samples. The only culture supernatants in which 
concentration of oxLDL was detected were the ones where PBMN were treated with IL-1β, but 
even so the average oxLDL concentration detected was low. In spite of these observations being 
consistent with the fact that surface Cp is increased in IL-1β treated PBMN, we cannot confirm 
at this time if GPI-Cp upregulation could be associated with oxidation of LDL, in a similar way 
as sCp [67]. In future experiments, a new incubation protocol should be optimized, in order to 
allow the measurement of sufficient levels of oxLDL in culture supernatants through ELISA 
technique a posteriori.  
In order to complement this in vitro study, laboratorial characterization of FH patients, 
considered here as a clinical model of ATH, was performed. Also, the search of putative 
biochemical and immunological associations was attempted to further understand the interaction 
of Fe/Cu, lipid metabolism and inflammation at systemic level in this pathology. Comparisons 
between the control group and FH patients, showed that several parameters related to lipid 
metabolism (total cholesterol, LDL, triglycerides, ApoB and Lp(a)), were found significantly 
increased in the patients, which was consistent with levels normally found in individuals with a 
genetic defect in cholesterol metabolism such as FH, as previously reported [174]. Ferritin, 
oxLDL and IL-1β levels were increased in FH patients, but the difference was not statistically 
significant. Unexpectedly, sCp and CRP levels in FH patients did not differ from the ones in 
controls, but this may be accounted for the fact that at the time of blood collection most of these 
patients were being medicated by statins. It has been reported that this therapy is able to reduce 
CRP levels [175] decreasing the inflammation status of the individuals. Also, it must be taken 
into account the fact that most patients’ serum samples were collected more than a year ago 
stored at -20ºC and, as such, some parameters might be influenced by time-dependent 
degradation in samples, particularly in the case of sCp. Moreover, several parameters were 
found to be correlated in FH patients and putatively associated with this ATH progression. sCp 
levels were positively correlated with CRP and oxLDL levels. These results are consistent with 
the fact both sCp and CRP are acute phase reactants and increased in inflammatory states [176], 
and the association between sCp and oxLDL gives further support to the reported pro-oxidant 
potential of sCp [67]. Furthermore, sCp was found to be negatively correlated with ferritin at 
systemic level, coherent with the ferroxidase role of sCp in Fe as it is negatively correlated with 
this storage protein and positively correlated with Tf (data not shown). Finally, in FH patients 
IL-1β levels were found to be positively correlated with total cholesterol and ApoB (the 
primary apolipoprotein of LDL), which are parameters commonly associated with increased 
CVD risk [177]. These observations were also in concordance with previous reports showing 
that individuals aﬀected by dyslipidemia and/or chronic stable angina have higher circulating 
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levels of the proinflammatory/atherogenic cytokine IL-1β [105, 178], and that the lack of IL-1β 
decreases the severity of ATH [106]. However, the fact that no correlation was encountered 
between IL-1β and oxLDL or sCp does not allow us to conclude that the increased levels of 
oxLDL in this population might be a consequence of Cp expression induced by IL-1β, at least at 
systemic level. One should note that one limitation of this clinical study was the impossibility of 
this laboratorial characterization of FH patients being performed with fresh serum samples and 
before medication was administered. Taken into account this limitation, additional studies 
should be performed in order to further clarify the importance of these observations in 
atherosclerotic process and ATH outcome. Also, until the role of both isoforms of Cp is fully 
determined and the importance of GPI-Cp cell specific expression and regulation in putative 
pro-atherogenic conditions is addressed, the relevance of this protein in pathologies such as 
ATH and CVD cannot be completely elucidated. Nevertheless, the observations made during 
this study are an important and original contribution to clarify this issue.  
Only through basic research one can start to understand the association between Fe/Cu 
status, lipid metabolism and inflammation in these processes. The fact that GPI-Cp was shown 
to be differently modulated by several of the putative pro-atherogenic treatments tested, and at 
times with opposite effects on PBMN compared to PBL, suggests the existence of specific cell-
type regulation of this protein that might be associated with different physiological roles in each 
cell type. A shortcoming in this study was the ineffectiveness in the association of PBMC 
surface Cp expression with oxidation of LDL, but this should be easily addressed in future 
experiments. Of notice, the pro-atherogenic IL-1β which in vitro significantly induced GPI-Cp 
in PBMN population was found with increased levels in our clinical model of ATH. However 
the fact that no correlation was able to be observed between IL-1β and sCp or oxLDL suggest 
that, at least at systemic level, IL-1β may not be contributing factor in enabling oxidation of 
LDL by sCp. 
In summary, the results of this study demonstrate that specific modulators of Fe/Cu status 
and inflammatory state putatively associated with ATH are involved in the modulation of Cp 
expression at surface of PBMC and thus, suggest that GPI-Cp could have a role in 
atherogenesis. Nevertheless, it is worth to mention that the complexity of ATH will not be 
explained only by the role of PBMC surface Cp and that the existence of other contributing 
factors and their interaction in plaque microenvironment should be fundamental pieces in the 
development of this disease, since “nature doesn’t recognize good or evil, only balance and 
imbalance” [179]. 
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FUTURE PERSPECTIVES 
 
After treatment with several modulators the obtained results from in vitro experiments 
showed significant decreases of GPI-Cp expression associated with increased cellular 
activation. This type of expression might reveal a situation of protein shedding, which was not 
possible to evaluate during the course of this study. Thus, it would be important to analyze 
stored cultured supernatants and evaluate the presence of Cp by Western blot. 
Several tested treatments were observed to be in contradiction with previous reports or with 
expected results. As such, the most promising treatments should be evaluated in different 
incubation conditions: IFN-γ, IL-2, IL-6, IL-8, M-CSF and TNF-α should be evaluated in 
shorter incubations periods to observe the immediate treatment effects on Cp expression, while 
reduced Cu status and SNAP treatment should be performed in longer incubations periods in 
order to evaluate the effect of protein stability in surface Cp expression levels. Due to time 
constraints it also proved to be difficult to test the effect of multiple modulators on GPI-Cp 
expression. As such, the evaluation of the effect of multiple pro-atherogenic stimuli co-
incubated in cell cultures would be of particular interest, as to better mimic the in vivo plaque 
microenvironment.  
One of the major limitations of this study was the failure to effectively evaluate the putative 
association between PBMC GPI-Cp expression and oxidation of LDL. The experimental 
protocol should be optimized to enable the incubation of native LDL in the appropriate 
conditions and the new designed experiments should also allow for the distinction of the 
secreted and membrane-bound Cp isoforms. In order to do so, after cellular stimulation with the 
selected treatment, supernatant and cell populations should be incubated separately in the 
presence of native LDL followed by the determination of oxLDL concentration induced by cells 
(GPI-Cp) or induced by supernatants (sCp). 
In order to further complement these in vitro experiments, basal Cp expression levels of 
PBMC should be evaluated in the clinical model of FH patients. It would be necessary to 
perform a new patient recruitment, preferably with individuals before starting statin therapy. 
The objective of this characterization should allow to evaluate in vivo the effect of inflammatory 
state, Fe/Cu status and dyslipidemia associated with this clinical model and the pathology of 
ATH. 
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Appendix I 
Table S I - Significant correlations between biochemical parameters in total individuals (n=80) 
Parameter versus r p < 
Total cholesterol LDL 0,917 < 0,001 
 
Lp(a) 0,424 < 0,001 
 
ApoB 0,833 < 0,001 
 
Triglycerides 0,366 = 0,001 
HDL ApoA1 0,914 < 0,001 
 
Triglycerides -0,317 < 0,01 
 
Transferrin 0,443 < 0,001 
 
Ferritin -0,358 = 0,001 
 
Cp 375 = 0,001 
LDL Lp(a) 0,438 < 0,001 
 
ApoB 0,901 < 0,001 
 
Triglycerides 0,362 = 0,001 
Lp(a) ApoB 0,308 < 0,01 
ApoA1 Transferrin 0,52 < 0,001 
 
Ferritin -0,356 = 0,001 
 
Cp 0,501 < 0,001 
ApoB Triglycerides 0,507 < 0,001 
Triglycerides CRP 0,228 < 0,05 
Iron Ferritin 0,312 < 0,01 
Transferrin Ferritin -0,529 < 0,001 
 
Cp 0,493 < 0,001 
Ferritin Cp -0,408 < 0,001 
CRP Cp 0,535 < 0,001 
 
 
 
Table S II - Significant correlations between biochemical parameters in FH patients (n=40) 
Parameter versus r p  
Total cholesterol LDL 0,975 < 0,001 
Lp(a) 0,438 < 0,01 
 
ApoB 0,838 < 0,001 
 
IL-1β 0,331 < 0,05 
HDL ApoA1 0,896 < 0,001 
 
Transferrin 0,348 < 0,05 
LDL Total cholesterol 0,975 < 0,001 
 
Lp(a) 0,470 < 0,01 
 
ApoB 0,861 < 0,001 
Lp(a) Total cholesterol 0,438 < 0,01 
ApoA1 HDL 0,896 < 0,001 
 
Transferrin 0,326 < 0,05 
ApoB Total cholesterol 0,838 < 0,001 
 Triglycerides 0,334 < 0,05 
 
IL-1β 0,345 < 0,05 
Triglycerides CRP 0,490 = 0,001 
Iron Ferritin 0,398 = 0,01 
Transferrin Ferritin - 0.428 < 0,01 
 CRP - 0,344 < 0,05 
Ferritin sCp - 0,359 < 0,05 
CRP sCp 0,375 < 0,05 
sCp oxLDL 0,523 = 0,001 
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Appendix II 
Poster presented at European Iron Club Meeting 2011, 8th-11th September,  
Louvain-la-Neuve, Belgium. 
 
